Advertisement
UK markets open in 4 hours 35 minutes

  • NIKKEI 225

    37,785.81
    -674.27 (-1.75%)
     

  • HANG SENG

    17,315.95
    +114.68 (+0.67%)
     

  • CRUDE OIL

    82.67
    -0.14 (-0.17%)
     

  • GOLD FUTURES

    2,330.90
    -7.50 (-0.32%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • Bitcoin GBP

    51,531.22
    -1,951.41 (-3.65%)
     

  • CMC Crypto 200

    1,387.92
    -36.18 (-2.54%)
     

  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Ligand (LGND) Inks Deal With Glenmark for OmniAb Platform

Zacks Equity Research
Updated

Ligand Pharmaceuticals Incorporated LGND announced that it has inked a worldwide license agreement with global innovative pharmaceutical company, Glenmark Pharmaceuticals. Per the agreement, Glenmark will be able to use the full OmniAb platform for producing mono- and bispecific human therapeutic antibodies.

Ligand will be entitled to receive to receive annual platform access payments, development and regulatory milestone payments and tiered royalties for each product incorporating an OmniAb antibody. Meanwhile, Glenmark will be responsible for all costs related to the programs. With the latest deal, Glenmark will also be able to access a technology that includes three separate species in a single license.

Notably, this is the first new OmniAb deal to include OmniChicken in addition to OmniRat, OmniMouse and OmniFlic.

OmniAb includes three transgenic animal platforms consisting of four different technologies— OmniRat, OmniMouse,OmniFlic and OmniChicken — for producing mono- and bispecific human therapeutic antibodies.

ADVERTISEMENT

Ligand’s shares have gained 39% in a year’s time compared with the industry’s growth of 1.1%.

We remind investors that OmniAb, an antibody-generating platform, became a part of Ligand’s technology portfolio following its OMT, Inc. acquisition in January 2016.

Ligand is focused on the development and licensing of biopharmaceutical assets. In fact, its Captisol formulation technology has allowed the company to enter into several licensing deals and generate royalties. Captisol is a well validated chemically modified cyclodextrin that is designed to improve safety and solubility, stability, and bioavailability or lessen the volatility, irritation, smell or taste of drugs.

Other technology platforms at Ligand include LTP technology and Selexis technology. All these technologies along with Captisol and OmniAb have created a strong platform for the company to seek new licenses and partnerships. Also, Ligand has partnership agreements with leading healthcare companies like Novartis NVS, Amgen, Merck MRK, Pfizer PFE, Celgene, Gilead and Lilly, among others.

Ligand Pharmaceuticals Incorporated Price

 

Ligand Pharmaceuticals Incorporated Price | Ligand Pharmaceuticals Incorporated Quote

Zacks Rank

Ligand has a Zacks Rank #5 (Strong Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks Editor-in-Chief Goes "All In" on This Stock

Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.

Download it free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Pfizer, Inc. (PFE) : Free Stock Analysis Report
 
Novartis AG (NVS) : Free Stock Analysis Report
 
Merck & Company, Inc. (MRK) : Free Stock Analysis Report
 
Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.